Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidylpeptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479–86.
CAS
PubMed
Google Scholar
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642–53.
CAS
PubMed
Google Scholar
Lepelley M, Khouri C, Lacroix C, Bouillet L. Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database. J Allergy Clin Immunol Pract. 2020;8(7):2406-8.e1.
PubMed
Google Scholar
Russell JS, Chi H, Lantry LE, Stephens RE, Ward PE. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides. 1996;17(8):1397–403.
CAS
PubMed
Google Scholar
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516–23.
CAS
PubMed
Google Scholar
Stone C Jr, Brown NJ. Angiotensin-converting enzyme inhibitor and other drug-associated angioedema. Immunol Allergy Clin N Am. 2017;37(3):483–95.
Google Scholar
Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34(Suppl 2):S276–8.
CAS
PubMed
PubMed Central
Google Scholar
Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110(3):383–91.
CAS
PubMed
Google Scholar
Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.
PubMed
PubMed Central
Google Scholar
Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. Int Immunopharmacol. 2020;78:106081.
CAS
PubMed
Google Scholar
Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100(4):327–32.
PubMed
Google Scholar
Carucci L, Bova M, Petraroli A, Ferrara AL, Sutic A, de Crescenzo G, et al. Angiotensin-converting enzyme inhibitor-associated angioedema: from bed to bench. J Investig Allergol Clin Immunol. 2020;30(4):272–80.
CAS
PubMed
Google Scholar
Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60(1):8–13.
CAS
PubMed
Google Scholar
Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509.
PubMed
Google Scholar
McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177–81.
CAS
PubMed
PubMed Central
Google Scholar
Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5(3):744–9.
PubMed
PubMed Central
Google Scholar
Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637–42.
CAS
PubMed
Google Scholar
Mahmoudpour SH, Baranova EV, Souverein PC, Asselbergs FW, de Boer A, Maitland-van der Zee AH, PREDICTION-ADR consortium. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2016;82(6):1647–59.
CAS
PubMed
PubMed Central
Google Scholar
Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, et al. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy. 2010;65(11):1381–7.
CAS
PubMed
Google Scholar
Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624–30.
CAS
PubMed
Google Scholar
Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55.
PubMed
Google Scholar
Pedrosa M, Prieto-García A, Sala-Cunill A, Spanish Group for the Study of Bradykinin-Mediated Angioedema (SGBA) and the Spanish Committee of Cutaneous Allergy (CCA). Management of angioedema without urticaria in the emergency department. Ann Med. 2014;46(8):607–18.
PubMed
Google Scholar
Hudey SN, Westermann-Clark E, Lockey RF. Cardiovascular and diabetic medications that cause bradykinin-mediated angioedema. J Allergy Clin Immunol Pract. 2017;5(3):610–5.
PubMed
Google Scholar
Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007;120(2):403–8.
CAS
PubMed
Google Scholar
Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51(1):141–7.
CAS
PubMed
Google Scholar
Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39(2 Pt 2):460–4.
CAS
PubMed
Google Scholar
Davin L, Marechal P, Lancellotti P, Martinez C, Pierard L, Radermecker R. Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors. Acta Cardiol. 2019;74(4):277–81.
PubMed
Google Scholar
Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. Hypertension. 2009;54(3):468–70.
CAS
PubMed
Google Scholar
Scott SI, Andersen MF, Aagaard L, Buchwald CV, Rasmussen ER. Dipeptidyl peptidase-4 inhibitor induced angioedema—an overlooked adverse drug reaction? Curr Diabetes Rev. 2018;14(4):327–33.
CAS
PubMed
Google Scholar
Williams R, Kothny W, Serban C, Lopez-Leon S, de Vries F, Schlienger R. Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study. Endocrinol Diabetes Metab. 2019;2(3):e00084.
PubMed
PubMed Central
Google Scholar
Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14.
PubMed
PubMed Central
Google Scholar
Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
PubMed
PubMed Central
Google Scholar
Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014;30(7):556–69.
CAS
PubMed
Google Scholar
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, SAVOR-TIMI 53 Steering Committee and Investigators, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
CAS
PubMed
Google Scholar
Cardiovascular outcomes study of alogliptin in patients with type 2 diabetes and acute coronary syndrome (EXAMINE). Study results. https://clinicaltrials.gov/ct2/show/results/NCT00968708.
Pfaue A, Schuler PJ, Mayer B, Hoffmann TK, Greve J, Hahn J. Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients. J Community Hosp Intern Med Perspect. 2019;9(6):453–9.
PubMed
PubMed Central
Google Scholar
Beaudouin E, Defendi F, Picaud J, Drouet C, Ponard D, Moneret-Vautrin DA. Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin. Eur Ann Allergy Clin Immunol. 2014;46(3):119–22.
CAS
PubMed
Google Scholar
Gabb G, Andrew N. Lump in the throat—a case study. Aust Fam Physician. 2013;42(12):863–6.
PubMed
Google Scholar
Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35(8):e60.
PubMed
PubMed Central
Google Scholar
Hahn J, Trainotti S, Hoffmann TK, Greve J. Drug-induced inhibition of angiotensin converting enzyme and dipeptidyl peptidase 4 results in nearly therapy resistant bradykinin induced angioedema: a case report. Am J Case Rep. 2017;18:576–9.
PubMed
PubMed Central
Google Scholar
Hermanrud T, Bygum A, Rasmussen ER. Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV. BMJ Case Rep. 2017;2017:bcr2016217802.
PubMed
PubMed Central
Google Scholar
Millot I, Plancade D, Hosotte M, Landy C, Nadaud J, Ragot C, et al. Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates. Br J Anaesth. 2012;109(5):827–9.
CAS
PubMed
Google Scholar
Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabet Med. 2013;30(4):e149–50.
CAS
PubMed
Google Scholar
Skalli S, Wion-Barbot N, Baudrant M, Lablanche S, Benhamou PY, Halimi S. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabet Med. 2010;27(4):486–7.
CAS
PubMed
Google Scholar
Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013;168(3):e106.
PubMed
Google Scholar
Arcani R, Martinez S, Gayet S. Sitagliptin and angioedema. Ann Intern Med. 2017;167(2):142–3.
PubMed
Google Scholar
Schneider A, Ramesh M. Angioedema following initiation of glecaprevir/pibrentasvir while on sitagliptin. J Allergy Clin Immunol Pract. 2019;7(6):2068–9.
PubMed
Google Scholar
Yeddi A, Abdelhai M, Mohamed AB, Yeddi O, Salih L, Ali M, et al. Alogliptin-associated angioedema: case report and review of the literature. Am J Ther. 2020. https://doi.org/10.1097/MJT.0000000000001214.
Article
PubMed
Google Scholar
Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13(4):337–44.
CAS
PubMed
Google Scholar
Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387–405.
CAS
PubMed
Google Scholar